Nurix Capital Surpluse from 2010 to 2025
| NRIX Stock | USD 12.58 0.76 5.70% |
Capital Surpluse | First Reported 2010-12-31 | Previous Quarter 815.6 M | Current Value 856.4 M | Quarterly Volatility 361.1 M |
Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 326 K, Net Interest Income of 23.8 M or Interest Income of 23.8 M, as well as many indicators such as Price To Sales Ratio of 24.85, Dividend Yield of 0.0 or PTB Ratio of 2.66. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
Nurix | Capital Surpluse |
Latest Nurix Therapeutics' Capital Surpluse Growth Pattern
Below is the plot of the Capital Surpluse of Nurix Therapeutics over the last few years. It is Nurix Therapeutics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nurix Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Surpluse | 10 Years Trend |
|
Capital Surpluse |
| Timeline |
Nurix Capital Surpluse Regression Statistics
| Arithmetic Mean | 298,450,572 | |
| Geometric Mean | 25,179,950 | |
| Coefficient Of Variation | 120.98 | |
| Mean Deviation | 333,511,268 | |
| Median | 2,733,000 | |
| Standard Deviation | 361,052,594 | |
| Sample Variance | 130359T | |
| Range | 854.5M | |
| R-Value | 0.90 | |
| Mean Square Error | 26210.7T | |
| R-Squared | 0.81 | |
| Slope | 68,351,046 | |
| Total Sum of Squares | 1955384.6T |
Nurix Capital Surpluse History
About Nurix Therapeutics Financial Statements
Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Surpluse | 815.6 M | 856.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.